Starting signal sounded: analytica 2012 to offer Early Bird discount

The starting signal has sounded for analytica 2012 in Munich. Application forms for the 23rd International Trade Fair for Laboratory Technology, Analysis and Biotechnology are available to interested companies. Also, a new offer is being introduced this year: For the first time ever, companies that register by January 31, 2011 will receive a five-percent Early Bird discount on selected stand space. Stand-space allocation for analytica 2012 was also moved forward considerably, i.e. to March 15, 2011.

"Preparations for analytica 2012 are already moving ahead at full speed. New application forms are now available," explains Susanne Grödl, Exhibition Director for analytica at Messe München. "As a result, things are moving along much earlier than in previous years, and we can offer our exhibitors an additional incentive: an Early Bird discount of five percent."

The discount applies to all stand space booked between September 1, 2010 and January 31, 2011, regardless of stand size and type (corner, row or island stand). The offer that is even worthwhile for smaller stands.

"The objective of this campaign is to give exhibitors an incentive to book their stand space early," adds Grödl. "After all, earlier registration allows us to move the entire planning process including visitor advertising considerably forward in time - which is something that exhibitors ultimately profit from."

Companies that do not automatically receive their application forms for the 2012 fair can download them directly at www.analytica.de/en/2012.

Most Popular Now

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...